The Natural Choice for Infected Fields96% Freedom from Re- infection at 5 Years1

97% Patency at 5 Years1

Life Restoring Technologies

CryoArtery®

Aortoiliac Artery

Patient Candidates

Clinical Outcomes: CryoArtery Aortoiliac Artery

The Ideal Graft for:

• Infected synthetic graft2,4,6,10-11

• Mycotic aneurysm2,4,6,10-11

• Aortoenteric fistula2,4,6,10-11

• Patients at high risk of infection2,4,6,10-11

• Patients requiring shortest operation time

• Patients who have no suitable autologous tissue for Neo-Aortoiliac System (NAIS) procedure

Infected Aorto-bifurcated Graft

CryoArteryAortoiliac Artery

Authors n Indication Follow Up Re- infection Rate Survival

Harlander- Locke, et al.1 220 Aortic graft Mean: 4% 75% (1 year) infection, enteric 30 months 51% (5 years) fistula/erosion, (1-160 months) infected pseudoaneurysm

McCready, et al.2 6 Infected aneurysms Range: 0% 50% 3 months to 5 years

McCready, et al.3 43 Infected graft, Mean: 2% 51% (90 days) primary aortic 46.4 months infection, fistula (1-112 months)

Noel, et al.4 56 Graft infection, Mean: 9% 75% AEF, mycotic 5.3 months aneurysm (0 -22 months)

Vardanian, et al.5 11 Graft infection Median: 5% 100% 4 years

Zhou, et al.6 42 Graft infection, Mean: 0% 79% AEF, mycotic 12.5 months aneurysm (3-39 months)

CryoArtery Aortoiliac Artery Vs. Alternative Procedures

Why CryoArtery Aortoiliac Artery?

• Shown to have resistance to gram positive, gram negative, and fungal pathogens2,4,6,10,11

• Structural durability: No reports of aneurysm or dilation in four US studies2,4,6,11

• “[A] safer, cheaper, and more effective treatment to mycotic aneurysms and infected vascular prosthesis than conventional techniques.”10

> Cost effective10

> Shorter hospital stay10

> Fewer days in ICU10

• Potential time savings in the operating room compared with alterative procedures1,5-9,11-19

Infected Endograft Infected Aorto-bifurcated Graft

CryoArtery NAIS* Axillofemoral Rifampin-Soaked Aortoiliac Artery1,5,6,11 Procedure Reconstruction8,9,13-19 Synthetic Graft9,10

Graft Re-infection 0%-9% 10%-14% 0%-25% 7%-47%

Mortality (30 day) 0%-17% 0%-20% 11%-28% 8%-18%

Mean OR Time 4-7 hours 5-12 hours* 6-10 hours* NR

Mean Length ofHospital Stay 16.7-24 days 21-28 days 18-33 days 30 days

*Some of these cases may have been performed as staged procedures.NR, Not reported

Tissues Diameter Length Catalogue Number

Aortoiliac Artery (Bifurcated) Aorta: 8 mm – 15 mmø 6 cm - 11+ cm R010 Iliacs: 4 mm – 5+ mm 4 cm -11+ cm

Descending Thoracic Artery 8 mm - 15 mmß 6 cm - 11+ cm A020ø Diameter distends up to approximately 39% at 120mmHg ß Diameter distends up to approximately 60% at 120mmHg

Femoral Artery 4 mm - 5+ mm 10 cm - 30+ cm R020

Femoral Vein 6 mm - 15 mm 10 cm - 30+ cm V060

Contact InfoPlace an order or ask technical questions any time (24 hours, 365 days a year) by calling 1-888-427-9654. Learn more at: www.cryolife.com/vascular

Femoral Vein Femoral Artery Aortoiliac Artery Descending Thoracic Artery

CryoArtery®

Aortoiliac Artery“The use of cryopreserved aortoiliac allografts is associated with lower rates of graft rupture, aneurysm formation, recurrent infection, and limb loss than other alternatives, so cryopreserved aortoiliac allografts should be considered a first line treatment against primary aortic graft infections.”20

Need additional conduit? Ask about femoral tissues and descending thoracic artery.

References:

1) Harlander-Locke, et al. J Vasc Surg. 2014 Mar;59(3):669-74.

2) McCready, et al. Ann Vasc Surg. 2006 Sep;20(5):590-5.

3) McCready, et al. J Surg Res. 2011 Jun 1;168(1):e149-53.

4) Noel, et al. J Vasc Surg. 2002 May;35(5):847-52.

5) Vardanian, et al. Am Surg. 2009 Oct;75(10):1000-3.

6) Zhou W, et al. Tex Heart Inst J. 2006;33(1):14-8.

7) Ali, et al. J Vasc Surg. 2009;50:30-9.

8) Liedenbaum , et al. Worl J Surg. 2009;33:2490-2496.

9) Bandyk, et al. J Surg Res. 2001;95(1):44-9.

10) Vogt, et al. J Thorac Cardiovasc Surg. 1998 Dec;116(6):965-72.

11) Brown, et al. J Vasc Surg. 2009 Mar;49(3):660-6.

12) Claggett, et al. J Vasc Surg. 1997 Feb;25(2):255-66

13) O’Hara, et al. J Vasc Surg. 1986 May;3(5):725-31.

14) Reilly, et al. J Vasc Surg. 1987 Mar;5(3):421-31.

15) Yeager, et al. J Vasc Surg. 1999 Jul;30(1):76-83.

16) Seeger, et al. J Vasc Surg. 2000 Sep;32(3):451-9; discussion 460-1.

17) Hart, et al. Ann Vasc Surg. 2005 Mar;19(2):154-60.

18) Schmitt, et al. J Cardiovasc Surg (Torino). 1990 May-Jun;31(3):327-32.

19) Bandyk, et al. J Vasc Surg. 2001 Sep;34(3):411-9.

20) Harlander-Locke, Current Vascular Surgery, Ch 35, 2014.

1655 Roberts Boulevard, NW • Kennesaw, Georgia 30144 • USA • Tel: 770 419 3355 • 800 438 8285 • Fax: 770 590 3753The AATB Accredited Institution logo is a registered trademark of the American Association of Tissue Banks and is used with permission of the AATB.

All other trademarks are owned by CryoLife, Inc. © 2014 CryoLife, Inc. All rights reserved.

ML0860.000 (11/2014)

Life Restoring Technologies